伊那魯單抗
| 單株抗體 | |
|---|---|
| 種類 | ? |
| 目標 | B細胞激活因子 |
| 臨床資料 | |
| 其他名稱 | VAY736、伊利尤單抗 |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1929549-92-7 |
| UNII | |
| KEGG | |
伊那魯單抗（INN：ianalumab；開發代號：VAY736），或譯伊利尤單抗，是一種單株抗體，正在被研究用於治療自身免疫性肝炎、多發性硬化症、尋常型天疱瘡、類風濕性關節炎、乾燥綜合症和系統性紅斑狼瘡。[1][2][3]
該藥物由諾華公司開發。2021年，伊那魯單抗正在進行II/III期試驗。[4][5]2023年6月伊那魯單抗參與了22項臨床試驗，其中3項已完成，14項正在進行，1項計劃中，4項終止。[6]
參考資料
[編輯]- ^ Ianalumab - MorphoSys/Novartis. AdisInsight. Springer Nature Switzerland AG. [2024-05-25]. （原始內容存檔於2021-08-10）.
- ^ van den Hoogen LL, van Laar JM. Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. Best Practice & Research. Clinical Rheumatology. February 2020, 34 (1): 101485. PMID 32067925. doi:10.1016/j.berh.2020.101485
.
- ^ Narain S, Berman N, Furie R. Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. Current Opinion in Rheumatology. November 2020, 32 (6): 609–616. PMID 33002950. S2CID 222150641. doi:10.1097/BOR.0000000000000754.
- ^ Clinical trial number NCT03574545 for "Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis" at ClinicalTrials.gov
- ^ Clinical trial number NCT03656562 for "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients" at ClinicalTrials.gov
- ^ Risk Adjusted Net Present Value: What is the current valuation of Novartis's Ianalumab. Pharmaceutical Technology. 30 June 2023 [2024-05-25]. （原始內容存檔於2023-09-23）.
